IMNN Imunon, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IMNN matters now
Imunon, Inc. (IMNN) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.02 with +0.50% on the session and $5.1M in market capitalization; recent performance reads 1-month -18.39% and YTD -52.23%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.2M, and EPS of $-0.84. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -328.1%.
The latest indexable market news headline is "IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Lindborg Stacy filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.72
P/S
0.00
EV/EBITDA
-0.05
DCF Value
$3.07
FCF Yield
-328.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-341.2%
ROA
-182.6%
ROIC
-346.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.2M | $-0.84 |
| Q4 2025 | $0.00 | $-4.2M | $-1.99 |
| FY 2025 | $0.00 | $-14.5M | $-6.83 |
| Q3 2025 | $0.00 | $-3.4M | $-1.16 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.93
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.